Primary tumors are a heterogenous group of neoplasms originating from brain. Since 2016 we have had the new WHO classification incorporating new molecular characteristics, in particular IDH mutational status and 1p19q codeletion. Glioblastoma represents the most frequent primary brain tumor in adults and numerous studies were performed analyzing new treatments, such as regorafenib showing interesting results. Moreover, we have new approaches for radiotherapy and neurosurgery. New approaches for magnetic resonance imaging and positron emission tomography are integrated into diagnostic and follow up steps. Low grade gliomas and other primary and secondary brain tumors such as meningiomas or lung or melanoma metastases showed interesting responses to new treatment, in particular to combination of radiotherapy, immunotherapy and targeted therapy.This special issue will cover all aspects of primary and secondary brain tumors including current treatment options, radiation therapy, surgery, immunotherapy, imaging and molecular characteristics. Reviews will also be gratefully accepted.
1. Giorgio Santoni School of Pharmacy, University of Camerino, Italy.
2. Alessia Pellerino From the Department of Neuro-Oncology (A.P., R.R., R.S.), University and City of Health and Science Hospital, Turin; and Oncology Department (L.B.), San Luigi Hospital, University of Turin, Orbassano, Italy.
3. Andrea Di Cristofori Division of Neurosurgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
4. Antonio Nicolato Department of Neurosciences, Unit of Stereotaxic Neurosurgery, Hospital Trust of Verona, Verona, Italy.
5. Luigi Corti Department of Radiotherapy, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
6. Gianmarco Pallavicini Department of Neurosciences, University of Turin, Turin, Italy.
7. Albert Girotti Department of Biochemistry, Medical College of Wisconsin, Milwaukee, USA.
8. Karar Almansory Institute of Nuclear Medicine, University College London Hospitals, London, UK.
9. Marco Zoccarato Neurology Unit, Ospedale S.Antonio, Padova, Italy.
10. Sergey V Roussakow Galenic Research Institute, Moscow, Russia.
11. Simona Rizzato Department of Translational Oncology and Services, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
12. Alessandro Frati Neuromed IRCCS, Neurosurgery, Pozzilli, Italy.
13. Carlo Giussani Unit of Neurosurgery, Department of Medicine and Surgery, Milan Centre for Neuroscience, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.
14. Claudia Caserta Medical Oncology, Dept. of Oncology, Azienda Ospedaliera S.Maria, Terni, Italy.
15. Bruno Giometto Neurology Unit, Rovereto Hospital, Azienda Provinciale per i Servizi Sanitari (APSS) di Trento, Trento, Italy.
16. John J. Rossi Department of Molecular and Cellular Biology, City of Hope, Duarte, USA.
17. Katherine Barnett Peters Neuro-Oncology, Surgery, Duke University, Durham, USA.
18. Patrick Sin-Chan Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada.
19. Mihir Shanker University of Queensland, Brisbane, Australia.
20. Sajeel Chowdhary Neuro-Oncology Program, Lynn Cancer Institute, Boca Raton, USA.
21. Stella E Tsirka Department of Pharmacological Sciences, Stony Brook University, Stony Brook, USA.
22. Ulrike Naumann Hertie-Institut für klinische Hirnforschung, Tubingen, Germany.
The list is arranged in no particular order and being updated.
Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JCMT/?IssueId=385
Submission Deadline: 31 Jan 2021
Contacts: Ivory Ma, Assistant Editor, email@example.com